Jim Birchenough
Stock Analyst at Wells Fargo
(2.83)
# 1,636
Out of 5,124 analysts
30
Total ratings
52.63%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.44 | +350.35% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $58.19 | +20.30% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $24.18 | +98.51% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.01 | +12,771.29% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $4.55 | +207.69% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $35.66 | +306.62% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $121.36 | -48.09% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $72.25 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $22.31 | +151.01% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $776.54 | -5.48% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.25 | +2,780.00% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $9.50 | +247.37% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.44
Upside: +350.35%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $58.19
Upside: +20.30%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $24.18
Upside: +98.51%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.01
Upside: +12,771.29%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $4.55
Upside: +207.69%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $35.66
Upside: +306.62%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $121.36
Upside: -48.09%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $72.25
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $22.31
Upside: +151.01%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $776.54
Upside: -5.48%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.25
Upside: +2,780.00%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $9.50
Upside: +247.37%